Radioimmunotherapy with 90Y-ibritumomab tiuxetan for a hemodialysis patient with relapsed follicular lymphoma.

about

The use of 90yttrium-ibritumomab tiuxetan in patients on dialysis: what do we know regarding its pharmacokinetics?

P2860

Q46510240-0E77D3CF-C85C-41F9-ADCD-25877834D022

P2860

Radioimmunotherapy with 90Y-ibritumomab tiuxetan for a hemodialysis patient with relapsed follicular lymphoma.

Item

http://www.wikidata.org/entity/Q45332759

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Radioimmunotherapy with 90Y-ib ...... relapsed follicular lymphoma.

@en

Radioimmunotherapy with 90Y-ib ...... relapsed follicular lymphoma.

@nl

type

Item

label

Radioimmunotherapy with 90Y-ib ...... relapsed follicular lymphoma.

@en

Radioimmunotherapy with 90Y-ib ...... relapsed follicular lymphoma.

@nl

prefLabel

Radioimmunotherapy with 90Y-ib ...... relapsed follicular lymphoma.

@en

Radioimmunotherapy with 90Y-ib ...... relapsed follicular lymphoma.

@nl

P1476

Radioimmunotherapy with 90Y-ib ...... relapsed follicular lymphoma.

@en

P2093

Hisashi Tsurumi

http://www.w3.org/2001/XMLSchema#string

Hisataka Moriwaki

http://www.w3.org/2001/XMLSchema#string

Kenji Fukuno

http://www.w3.org/2001/XMLSchema#string

Takayoshi Iida

http://www.w3.org/2001/XMLSchema#string

Takeshi Takahashi

http://www.w3.org/2001/XMLSchema#string

Toshiki Yamada

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

P304

2731-2733

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2013.783213

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23480494

http://www.w3.org/2001/XMLSchema#string

Radioimmunotherapy with 90Y-ibritumomab tiuxetan for a hemodialysis patient with relapsed follicular lymphoma.

about

P2860

P2860

Radioimmunotherapy with 90Y-ibritumomab tiuxetan for a hemodialysis patient with relapsed follicular lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698